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Abstract
The concurrence of multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) is exceedingly rare and the
pathological features have not been examined extensively. Here we describe the key pathological features of a 40
year old man with pathologically confirmed concurrent MS and ALS.
This is the most pathologically illustrative case of coincident MS and ALS demonstrating inflammatory and
neurodegenerative features characteristic of each disease, and is the first to exhibit the presence of TDP-43
inclusions in this clinical entity. The intricate relationship between neuroinflammation and neurodegeneration in
these diseases is discussed.
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Background
MS has been traditionally viewed as an inflammatory
demyelinating disease of the central nervous system
with a secondary degenerative component whereas ALS
has been considered a primary central and peripheral
nervous system degenerative disorder with a secondary
inflammatory component. In both diseases, neurological
disability accrues secondary to axonal loss. While they
appear on opposite ends of the inflammatory/degenera-
tive spectrum, the relationship between neuroinflamma-
tion and neurodegeneration is likely more dynamic and
interactive than merely consequential as historically
described. Here we present a rare case of MS and ALS
within the same patient and provide an overview of the
complex interplay between neuroinflammation and neu-
rodegeneration in these diseases.
Case presentation
A 37 year old man presented with a left VIth cranial
nerve palsy and nystagmus that improved on a brief
course of steroids. A diagnosis of possible MS was
entertained. Two years later, he experienced a subacute
episode of bilateral leg weakness that was steroid
responsive, prior to which he had a several month his-
tory of gradual decline in cognition, decreased visual
acuity, widespread fasciculations with asymmetric upper
limb weakness, and bilateral appendicular and truncal
ataxia. The subsequent 12 months were notable for the
evolution of debilitating lethargy and fatigue, and pro-
gressive dysarthria and dysphagia. He died of respiratory
compromise at the age of 40.
Pathology
Formalin-fixed paraffin-embedded sections of pre-frontal
and sub-frontal cortex, hippocampus, cerebellum, pons,
low and high cervical and thoracic, lumbar and sacral
spinal cord were stained with Luxol Fast Blue and Cre-
syl Violet (LBCV), Palmgren silver, Proteolipid protein
(PLP), CD68 (PG-M1), CD3, and TDP-43 antibodies
(Figure 1). Using the LCBV stain, anterior horn cells
(AHC) were identified quantified and compared to
counts from two age- and sex-matched controls using
established methods.
Pathological confirmation of MS was supported by
evidence of multiple discrete areas of inflammatory
demyelination in prototypic locations, including cortex
(subpial, leukocortical), periventricular region, corpus
callosum (Figure 1A, B), pons (Figures 1E, F), cerebellar
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spinal cord (Figure 1G). Microscopically, lesions were
characterized by infiltration of macrophages in the epi-
center of acute lesions and the border of chronic active
lesions (Figure 1C); perivascular lymphocytic cuffing was
noted in both (Figure 1D). Lesions of all stages of
demyelinating activity were observed, with acute lesions
being predominant. An extensive demyelinating lesion
involving all layers of the hippocampus was the likely
substrate for the patient’s significant cognitive difficulty
during life. Axonal density appeared to be mildly
reduced in plaques when compared to surrounding nor-
mal appearing white matter. Meningeal inflammation
with monocytic infiltrates was observed often without
underlying subpial demyelination. No evidence of TDP-
43 inclusions were noted in any of the MS lesions
studied.
There were several classic features of ALS pathology
in areas distinct from MS plaques. Ventral nerve roots
were discoloured and selectively thinned (Figure 1I), and
a marked reduction (approximately 75%) of anterior
horn cells at multiple serial lumbosacral cord levels
when compared to controls was observed (Figure 1K, L).
Microglial activation was noted in i) layer V of the
motor cortex (where Betz cells were sighted), and ii) at
various levels of the spinal cord (Figure 1H). Corticosp-
inal tract axonal loss appeared to be size selective, with
large fibres particularly affected - a finding previously
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Figure 1 Neuropathological features of concurrent MS and ALS. Left hemispheric leukocortical (within box) and periventricular lesions
(arrow) (A). PLP staining of leukocortical plaque in A (inlay) demonstrating demyelination spanning grey and white matter (B), PG-M1 staining
showing macrophage infiltration and microglia activation (C), and perivascular cuffing with cells resembling lymphocytes (D) within same lesion.
Gross (E) and PLP-stained section (F) of pons (with cerebellum) demonstrating periventricular and parenchymal demyelination. PLP-stained
section of demyelinated lesion in dorsal column of cervical spinal cord (arrow) (G) with diffuse microglia activation extending beyond lesional
borders (PG-M1 staining) (H). Gross view of thinned and discolored ventral roots of lower cervical cord from case (I) compared to control (J).
LBCV section of lumbar cord demonstrating significant loss of anterior horn cells in the case (K) compared to control (L). TDP-43 staining
demonstrating intracytoplasmic neuronal inclusions in anterior horn cells in lumbar spinal cord (arrowheads) in case (M) compared to nuclear
neuronal staining of the same area in a control (N).
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(where small fibres are preferentially lost) [2]. Anterior
horn cells in both cervical and lumbar cord demon-
strated intracytoplasmic TDP-43 positive inclusions (Fig-
u r e1 M ) ,w i t hn oe v i d e n c eo fs u c hi n c l u s i o n si nt h e
cortical and deep gray matter regions examined. FUS
staining was negative in all areas studied.
Discussion
Post-mortem confirmation of concomitant ALS with MS
has been verified only three times previously in the lit-
erature. Hader et al. [3] documented the case of a 56
year-old gentleman with a 27 year history of relapsing-
remitting MS who, after 8 years of remission, developed
bulbar signs with fasciculations, weakness and atrophy.
Confavreaux et al. [4] described a similar story of a 25
year-old female who presented with MS and after a 10
year quiescent period again developed a similar range of
ALS-like symptoms. Dynes et al. [5] described a case of
a 62-year lady presenting with progressive quadriplegia
and bulbar palsy who also experienced symptoms con-
sistent with Lhermitte’s phenomenon and paresthesia
within an overlapping timeframe of just several months.
Here we present yet another case of pathologically con-
firmed coincident MS and ALS and highlight the emer-
ging overlap between these respectively viewed
inflammatory and neurodegenerative diseases.
i) Inflammation in MS and ALS
Whether inflammation is a cause or effect of the pri-
mary pathology, similar immunological profiles have
been observed in both diseases. Both innate and adap-
tive arms of the immune response have been implicated
in the pathogenesis of MS. Generalised activation of
microglia, astrocytes and autoreactive T and B lympho-
cytes play a role in maintaining disease. There is evi-
dence for involvement of specifically the Th17
population in perpetuating inflammation, in particular
in association with production of IL-12 [6].
Pro-inflammatory cell populations are important in
ALS too. RT-PCR in ALS patients of spinal cord white
and gray matter has shown increased glial expression of
toll-like receptor proteins [7]. Raised serum and CSF IL-
12 and IL-17, levels in ALS patients, and high serum IL-
23 levels point towards a similar cytokine and T-cell
activation profile being present in both ALS and MS [8].
Increased levels of IL-13-producing T-cells correlate
positively with ALS disease progression and severity.
Clinically, it is intriguing that cannabinoid-receptor
antagonists, through their anti-inflammatory effects,
have been shown to be efficacious in the symptomatic
management of not only MS, but also of ALS [9].
Inflammatory cell populations need not always be det-
rimental to neuronal survival, sometimes conferring a
degree of neuroprotection. Microglia produce neuro-
trophic factors which directly assist with regeneration,
such as neurotrophin 3 and brain-derived neurotrophic
factor. There is recent evidence that activated T cell
populations may also be crucial in neuroprotection, pos-
sibly in association with the secretion of IL-4 [10], asso-
ciated with downstream production of insulin growth
factor (IGF1). These protective inflammatory mechan-
isms may be important in both MS and ALS.
ii) Degeneration in ALS and MS
Regardless of whether inflammation is a primary or sec-
ondary cause of pathology, the molecular basis of axonal
loss in both diseases may converge on similar mechan-
isms. Microglia and astrocytes are instrumental in ALS
models; selective knockout of microglia in SOD1 mutant
mice has been shown to delay disease onset and pro-
gression. Glial cells are also hypothesised to amplify the
degenerative process by activating NF-b by an inflam-
matory cytokine cascade, which incorporates the pro-
apoptotic molecules FAS ligand and TDP-43 [11]. In the
SOD1 models, nerve growth factor produced by acti-
vated astrocytes was associated with the death of motor
neurons in the presence of NO and peroxide production
[12]. Microglial cells may form part of a degradation
pathway mediated by excitotoxicity as alterations in
metabotropic glutamate receptor expression have been
seen in human spinal cord [13].
Similar to ALS, MS pathology demonstrates activated
microglia and astrocytes known to produce NO and
reactive oxygen species. In MS, the presence of these
reactive species may lead to degeneration of both the
neuron and myelin sheath. Secretion of IL-23 and osteo-
pontin also leads to downstream production of TNF-a,
promoting myelin degradation [6]. The activation of
NF-b via an inflammatory cytokine cascade initiated
and propagated by microglia and astrocytes has also
been shown to occur in MS with the downstream con-
sequence of neuronal/axonal degeneration. Glutamate
excitotoxicity is increasingly recognized as an important
feature of both myelin and axonal destruction in MS, a
feature which has prompted the use of anti-glutaminer-
gic agents often used in ALS, such as riluzole, in experi-
mental animal models of MS [14].
Conclusions
We present an unusual case of a pathologically con-
firmed coincident MS and ALS. Axonal loss, the sub-
strate for irreversible neurological disability, is a shared
pathologic feature in both conditions with intriguing
similarities emerging in the molecular and cellular path-
ways leading to axonal demise. Given the underwhelm-
ing impact of current therapies to prevent disability in
MS and ALS, efforts directed at understanding the
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tion in both MS and ALS will be essential to develop
therapies designed to halt the devastating consequences
of these diseases.
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